Alteraciones vasculares en la insuficiencia renal crónica. Papel del endotelio.

Source: OAI

ABSTRACT RESUMEN El síndrome urémico resulta de la disminución marcada de la función renal. Este estado mantenido conduce a la insuficiencia renal crónica, que se define como la destrucción progresiva e irreversible de las nefronas. En la insuficiencia renal crónica se dan cita diferentes factores de riesgo cardiovascular, la propia uremia supone un factor de riesgo. La causa principal de morbi-mortalidad en estos pacientes deriva de alteraciones en el sistema cardiovascular. El tratamiento mediante hemodiálisis ha supuesto la prolongación de la vida para estos enfermos, pero a la vez, ha acarreado problemas relacionados con alteraciones cardiovasculares. En la presente tesis se estudian las vías de síntesis de factores endoteliales que pueden estar alteradas por la enfermedad y que pueden ser las responsables, al menos en parte, de las alteraciones vasculares que padecen estos enfermos. Nos centramos en la participación de los factores endoteliales relajantes: prostaciclina, NO y EDHF, observando que la uremia produce una disminución de su síntesis o liberación en respuesta a estímulos vasodilatadores y vasoconstrictores. Las alteraciones vasculares que puede ocasionar el tratamiento con hemodiálisis, ha puesto de manifiesto que aunque disminuye la participación de NO en la respuesta vascular, aumenta la de EDHF. Estos resultados son importantes, pues suponen la aparición de un mecanismo compensatorio, capaz de mejorar la función endotelial. El estudio de la expresión de genes implicados de manera directa o indirecta en la reactividad vascular sugiere que la enfermedad podría tener su origen en un fallo metabólico, puesto que nuestros resultados muestran una menor expresión génica de DDAH-1. Esta enzima es la encargada de metabolizar las toxinas que se acumulan en la uremia y que son inhibidores enzimáticos, causando gran parte de la disfunción vascular y alteraciones neurológicas que aparecen en esta enfermedad. Las modificaciones enzimáticas que hemos observado en la insuficiencia renal crónica podrían ser dianas terapéuticas para mejorar la calidad de vida en estos enfermos. __________________________________________________________________________________________________ Uremia is an established risk factor for cardiovascular and cerebrovascular accidents. Hemodialysis improves the lifes quality of these patients, but this treatment also produces vascular alterations. We examined the relaxant and contractile response in forearm veins from patients with chronic renal failure before hemodialysis, on chronic hemodialysis and in veins obtained from donors (controls). We study the role of vasodilator prostaglandins (PGI2), nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF). The contribution of these factores is diminished in chronic renal failure. This effect might contribute to, or even cause, some of the vascular features of this condition. Hemodialysis improves the endothelial function because of an augmented participation of EDHF. The study of gene expression showed a metabolic failure in the enzyme that degrades the uremic toxins. The low expression of this enzyme, dimethylarginine dimethylamino hydrolase (DDAH), could explain some vascular features and could be a therapeuthic strategy for improving lifes quality of these patients.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cardiovascular complications are a major clinical problem in patients with chronic kidney disease and end-stage renal failure; cardiac death accounts for approximately 40-50% of all deaths in these patients. Death from cardiovascular causes is up to 20 times more common in uremic patients than in the general population with the risk being even higher than in patients with diabetes mellitus. A high rate of myocardial infarction and excessive cardiac mortality have repeatedly been documented in patients with kidney disease and renal failure. Not only is the prevalence of myocardial infarction high, but also the case fatality rate is significantly higher in uremic patients with and without diabetes, respectively, compared to nonuremic patients. This is of particular interest since the prevalence of coronary atheroma in uremic patients was shown to be approximately 30% by autopsy and coronary angiography studies. Thus, coronary factors, i.e. atherosclerosis, and non-coronary factors may play an important role in the genesis of cardiac complications in the renal patient. In addition, renal failure recently has also be identified as a predictor of mortality in different stages of peripheral vascular disease. In particular, marked differences in the pathogenesis, morphology and course of atherosclerosis and arteriosclerosis under the conditions of renal failure have been documented. Among others increased plaque formation and particularly higher proportion and intensity of vascular calcification have been found in clinical and autopsy studies. In addition to the so-called classical or traditional risk factors, an important role for nonclassical risk factors such as microinflammation, hyperphosphatemia and oxidative stress has been documented in patients with renal failure and is discussed in detail.
    Kidney and Blood Pressure Research 02/2005; 28(5-6):280-9. DOI:10.1159/000090182 · 1.82 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cardiovascular disease is a leading cause of death after renal transplantation with an incidence considerably higher than that in the general population. The aim of this study was to evaluate the association of atherosclerotic cardiovascular complications and the prevalence of cardiovascular risk factors prior to and following transplantation. Atherosclerotic cardiovascular diseases including coronary artery disease, as well as cerebral and peripheral vascular disease, and cardiovascular risk factors pre- and posttransplantation were analyzed in 500 renal transplant recipients between 1988 and 1992. The mean recipient age at transplantation was 45 +/- 12 years, with 58% men and 7% diabetics. Following transplantation 11.7% developed atherosclerotic cardiovascular diseases, the majority being coronary artery disease (9.8%). Comparison of the risk factors before and after transplantation showed the increased prevalence of systemic hypertension to be 67% to 86%, of diabetes mellitus, 7% to 16%, and obesity, with a body mass index > 25 kg/m2 from 26% to 48%, whereas the number of smokers was halved to 20%. The triglycerides decreased significantly (from 235 +/- 144 mg/dL to 217 +/- 122 mg/dL) but the total and high-density lipoprotein (HDL) cholesterol rose significantly (from 232 +/- 65 mg/dL to 273 +/- 62 mg/dL and from 47 +/- 29 mg/dL to 56 +/- 21 mg/dL, respectively). The low-density lipoprotein (LDL) cholesterol increase was insignificant (from 180 +/- 62 mg/dL to 189 +/- 53 mg/dL). Upon univariate analysis, cardiovascular diseases were significantly associated with male gender; age over 50 years; diabetes mellitus (DM); smoking; total cholesterol > 200 mg/dL; LDL cholesterol > 180 mg/dL; HDL cholesterol < 55 mg/dL; fibrinogen > 350 mg/dL; body mass index > 25 kg/m2; and more than two antihypertensive agents per day. The Cox proportional hazards model revealed DM with a relative risk (RR) of 4.3; age > 50 years (RR = 2.7); body mass index > 25 kg/m2 (RR = 2.6); smoking (RR = 2.5); and LDL cholesterol > 180 mg/dL (RR = 2.3) as independent risk factors. The high incidence of cardiovascular disease following renal transplantation is mainly due to a high prevalence and accumulation of classical risk factors before and following transplantation. The treatment of risk factors must be introduced early in the course of renal failure and continued following transplantation. Future prospective studies should evaluate the success of treatment regarding reduction of cardiovascular morbidity and mortality in this high-risk population.
    Transplantation Proceedings 03/2006; 38(2):506-8. DOI:10.1016/j.transproceed.2006.01.001 · 0.95 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Endothelium-derived relaxing factor (EDRF) is a labile humoral agent which mediates the action of some vasodilators. Nitrovasodilators, which may act by releasing nitric oxide (NO), mimic the effect of EDRF and it has recently been suggested by Furchgott that EDRF may be NO. We have examined this suggestion by studying the release of EDRF and NO from endothelial cells in culture. No was determined as the chemiluminescent product of its reaction with ozone. The biological activity of EDRF and of NO was measured by bioassay. The relaxation of the bioassay tissues induced by EDRF was indistinguishable from that induced by NO. Both substances were equally unstable. Bradykinin caused concentration-dependent release of NO from the cells in amounts sufficient to account for the biological activity of EDRF. The relaxations induced by EDRF and NO were inhibited by haemoglobin and enhanced by superoxide dismutase to a similar degree. Thus NO released from endothelial cells is indistinguishable from EDRF in terms of biological activity, stability, and susceptibility to an inhibitor and to a potentiator. We suggest that EDRF and NO are identical.
    Nature 06/1987; 327(6122):524-6. DOI:10.1038/327524a0 · 42.35 Impact Factor
Show more


Available from